Our early Earth was a heavy metal album cover: a molten ball covered in a global lava ocean, spewing lethal gases while being pelted by the flaming space-rocks of our Solar System’s violently chaotic afterbirth.
Over the next 4.5 billion years of hectic cosmo-geological time, it has settled down a bit, allowing humans, lemurs, and others to emerge.
A vision of this hellish ancient reality remains, (hopefully) never to be glimpsed by human eyes: our molten metallic core, blazing about as hotly as the surface of the Sun.
Artificial intelligence may transform molecular biology not by always providing the correct answer, but by exploring mechanistic possibilities unconstrained by the assumptions that shape expert thinking. Its greatest contribution may be exposing the intellectual blind spots of scientists, while experimental validation remains the ultimate arbiter of truth.
Blanke P, Weir-McCall JR, Achenbach S, et al. Computed Tomography Imaging in the Context of Transcatheter Aortic Valve Implantation (TAVI)/Transcatheter Aortic Valve Replacement (TAVR): An Expert Consensus Document of the Society of Cardiovascular Computed Tomography. JACC Cardiovasc Imaging 2019;12:1–24.
Georgia Tech researchers are exploring new frontiers in neuroethics: to ensure that emerging neurotechnologies can be used for the good of all and to ensure that we won’t inadvertently relinquish crucial human rights which have yet to be legally defined.
As neuroscience and neurotechnology accelerate, Georgia Tech researchers are examining what a neuro-connected future could mean for society and for humanity itself.
Tonsil-derived fibroblasts support B cell activation and proliferation in response to stimulation in ex vivo 3D co-culture. However, when rendered senescent using bleomycin, tonsil-derived fibroblast…
Gliogenesis is a multistep process in which glial progenitors are specified into migrating and proliferating precursor cells that subsequently differentiate into mature astrocytes and oligodendrocytes. How these developmental processes are coordinated to generate the diverse glial lineages across gray matter (GM) and white matter (WM) remains poorly understood. Here, we show that the basic-helix-loop-helix (bHLH) transcription factor ASCL1 serves as a direct mechanistic link between these processes in the dorsal forebrain. Notably, ASCL1 is dynamically expressed in glial progenitor cells, initiating in the ventricular zone (VZ), peaking in the intermediate zone (IZ), but is downregulated once glial cells enter the cortical plate. Lineage tracing of ASCL1+ progenitors demonstrates that they subsequently co-express OLIG2 to generate both astrocytes and oligodendrocytes in an “outside-in” pattern starting from the upper cortex inward to the corpus callosum, the opposite pattern of neurogenesis. ASCL1 gain-of-function combined with OLIG2 loss-of-function reveals that sustained levels of ASCL1 are essential to induce sufficient levels of OLIG2 required to specify oligodendrocyte precursor cell (OPC) fate. Interestingly, a persistent ASCL1 expression also maintains OPCs in an undifferentiated, pre-neoplastic state into postnatal stages, in part by suppressing their differentiation into postmitotic oligodendrocytes. Together, these findings establish ASCL1 as a key regulator of the spatiotemporal order of glial lineage diversity in cortical GM and callosal WM, and highlight ASCL1 dysregulation as an underlying developmental mechanism in the pathogenesis of gliomas.
Significance statement The brain relies on macroglia to form the blood-brain-barrier, insulate nerve fibers, and regulate neuronal signaling; yet how these cell types are generated remains poorly understood. This study shows that the timing and levels of two key regulatory proteins, ASCL1 and OLIG2, function together to guide immature glial cells through distinct stages of development. Notably, we show that brief ASCL1 activity followed by sustained ASCL1 and OLIG2 levels coordinate when glial cells form, the cell type they become, and where they migrate to reside in the cerebral cortex. By revealing the developmental program underlying the generation of glial cell diversity, this study provides a framework for understanding how glial-related neurological diseases and cancer arise in the brain.
Three people going blind got one injection designed to make their old eye cells young again. Eight weeks later, two of them could see better. These are the first human results from age-reversal gene therapy.
In this episode of Health Longevity Secrets, Robert Lufkin MD breaks down the first-in-human data for ER-100, Life Biosciences’ epigenetic reprogramming therapy for glaucoma, presented October 8, 2026. You’ll learn how the OSK (Yamanaka factor) genes reset old retinal cells, what the safety data showed, what a 4-decibel visual field gain really means, how the therapy guards against cancer, and why three patients with no placebo group is a first step, not proof.
CHAPTERS: 00:00 — Introduction: First Human Results of Age Reversal. 00:28 — Recap: Human Age Reversal Has Begun. 00:44 — Glaucoma: Why Lost Vision Can’t Be Restored Today. 00:59 — Harvard 2020: OSK Genes Restore Vision in Old Mice. 01:29 — ER-100 Phase 1 Trial: First Human Results. 02:05 — ER-100 Safety Data Through Day 56 02:28 — 2 of 3 Glaucoma Patients Improved Their Vision. 02:48 — What a 4 dB Visual Field Gain Really Means. 03:42 — Does Cellular Reprogramming Cause Cancer? 04:17 — Will Age Reversal Arrive in Our Lifetime? 04:40 — Beyond Glaucoma: Macular Degeneration and Other Diseases. 04:59 — Honest Caveats: 3 Patients, No Placebo, Learning Effect. 06:04 — The Takeaway: The Race to Reverse Aging.
KEY TAKEAWAYS: • ER-100 is the first therapy built to reverse cellular aging to be tested in people: 3 glaucoma patients, one eye injection at the lowest dose, plus doxycycline as the on-switch for 8 weeks. • Safety was clean through day 56: no dose-limiting toxicities and no serious adverse events attributed to the gene therapy. • 2 of 3 patients improved on the Humphrey visual field test, with at least 28% of tested points improving by more than 4 dB (about 2.5x dimmer light detected). • An independent safety board approved tripling the dose for the next patients. • The therapy leaves out c-Myc, a known cancer gene, and has an off switch; patients will be followed until about 2032. • Big caveats: 3 patients, no placebo, open-label, a noisy test with a known learning effect, and a company presentation rather than a peer-reviewed paper.
STUDIES & SOURCES MENTIONED: • Life Biosciences — First-in-human data from the ongoing Phase 1 trial of ER-100 (Oct 8, 2026) — https://www.lifebiosciences.com/life–… • Lu et al., Nature 2020 — Reprogramming to recover youthful epigenetic information and restore vision — https://pubmed.ncbi.nlm.nih.gov/33268… • ClinicalTrials.gov NCT07290244 — Evaluating ER-100 for Safety in Optic Neuropathies — https://clinicaltrials.gov/study/NCT0… • Gillespie et al., Invest Ophthalmol Vis Sci 2003 — CIGTS visual field test-retest variability — https://pubmed.ncbi.nlm.nih.gov/12766… • Business Insider — Silicon Valley billionaires and cellular reprogramming (Oct 2026) — https://www.businessinsider.com/billi… • Previous episode — Human Age Reversal Has Begun — • Human Age Reversal Has Begun.
This video is for educational purposes only and is not medical advice.
Quantum computing has turned into a phrase that the tech industry will sprinkle on almost anything to help raise funds and generate sales. As a result, there is a tsunami of hype about what quantum computers are going to revolutionise. Join leading quantum computing specialist Scott Aaronson as he challenges the hype and tells us what is really going on.
